Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Gyre Therapeutics (GYRE) Non-Current Receivables (2023 - 2024)

Gyre Therapeutics (GYRE) has disclosed Non-Current Receivables for 2 consecutive years, with $5.0 million as the latest value for Q4 2024.

  • Quarterly Non-Current Receivables rose 5.89% to $5.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2024, up 5.89% year-over-year, with the annual reading at $5.0 million for FY2024, 5.89% up from the prior year.
  • Non-Current Receivables for Q4 2024 was $5.0 million at Gyre Therapeutics, up from $4.9 million in the prior quarter.
  • The five-year high for Non-Current Receivables was $5.0 million in Q4 2024, with the low at $4.6 million in Q1 2023.